Lipid-Induced Immune Activation Responsible for Increased Myeloma Risk in Gaucher's Disease
By LabMedica International staff writers Posted on 23 Feb 2016 |
Image: Hereditary deficiency of the enzyme glucocerebrosidase (also known as glucosylceramidase or acid beta-glucosidase) is the cause of Gaucher\'s disease (Photo courtesy of Wikimedia Commons).
Analysis of tissue and blood samples from mice and human patients with Gaucher's disease showed that an increased risk for development of myeloma was linked to long-term immune activation by lysophospholipids.
Lysophospholipids are small bioactive lipid molecules characterized by a single carbon chain and a polar head group. Two subgroups can be distinguished: molecules containing the sphingoid base backbone (lysosphingolipids) and molecules containing the glycerol backbone (lysoglycerophospholipids). The lysolipid structure renders these lipids more hydrophilic and versatile than their corresponding phospholipids.
Investigators at Yale University (New Haven, CT, USA) had shown previously that patients with Gaucher's disease, an inherited lipid storage disorder, had a significantly increased risk for developing myeloma.
In the February 11, 2016, issue of the New England Journal of Medicine, these investigators reported that gammopathy (a precursor to myeloma) in both mice and patients with Gaucher's disease was initiated by specific lipids, such as lyso-glucosylceramide (LGL1), and that the antibodies made by tumor cells in nearly a third of myeloma patients were directed against such lipids.
“Understanding the origin of any cancer has several implications for how to best prevent it,” said senior author Dr. Madhav Dhodapkar, professor of medicine and immunobiology at Yale University. “These studies set the stage for newer approaches to lower the levels of these lipids in patients with Gaucher's disease and others with precursors for myeloma. Potentially, this could be achieved with drugs or lifestyle changes to reduce the levels of lipids to lower the risk of cancer.”
Related Links:
Yale University
Lysophospholipids are small bioactive lipid molecules characterized by a single carbon chain and a polar head group. Two subgroups can be distinguished: molecules containing the sphingoid base backbone (lysosphingolipids) and molecules containing the glycerol backbone (lysoglycerophospholipids). The lysolipid structure renders these lipids more hydrophilic and versatile than their corresponding phospholipids.
Investigators at Yale University (New Haven, CT, USA) had shown previously that patients with Gaucher's disease, an inherited lipid storage disorder, had a significantly increased risk for developing myeloma.
In the February 11, 2016, issue of the New England Journal of Medicine, these investigators reported that gammopathy (a precursor to myeloma) in both mice and patients with Gaucher's disease was initiated by specific lipids, such as lyso-glucosylceramide (LGL1), and that the antibodies made by tumor cells in nearly a third of myeloma patients were directed against such lipids.
“Understanding the origin of any cancer has several implications for how to best prevent it,” said senior author Dr. Madhav Dhodapkar, professor of medicine and immunobiology at Yale University. “These studies set the stage for newer approaches to lower the levels of these lipids in patients with Gaucher's disease and others with precursors for myeloma. Potentially, this could be achieved with drugs or lifestyle changes to reduce the levels of lipids to lower the risk of cancer.”
Related Links:
Yale University
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples